Ex-Alembic executive pleads guilty in U.S. generic drug price-fixing scheme

WASHINGTON (Reuters) – A former executive of Alembic Pharmaceuticals Ltd pleaded guilty on Friday to participating in a scheme to fix prices for generic medicines. The Justice Department said former executive Hector Armando Kellum had pleaded guilty to working to fix the prices of clobetasol, used to treat eczema and psoriasis, and nystatin triamcinolone cream, an anti-fungal drug that also has a corticosteroid. Alembic’s website lists Kellum as a vice president of sales and marketing. Kellum, contacted through Alembic, did not respond to a request for comment. The government said one of Kellum’s alleged co-conspirators was Ara Aprahamian, a former sales and marketing executive at Taro Pharmaceutical Industries Ltd, who was also indicted for price-fixing and bid-rigging. U.S. drug pricing has become a political issue in recent years amid complaints that some drugs, including medicines on the market for decades, have seen sharp price increases.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s